Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 36

1.

WHO/Health Canada meeting on regulatory considerations for evaluation and licensing of new meningococcal Group B vaccines, Ottawa, Canada, 3-4 October 2011.

Feavers I, Griffiths E, Baca-Estrada M, Knezevic I, Zhou T.

Biologicals. 2012 Nov;40(6):507-16. doi: 10.1016/j.biologicals.2012.09.008. Epub 2012 Oct 16.

PMID:
23078946
2.

Meningococcal serogroup B vaccines: Estimating breadth of coverage.

Donald RG, Hawkins JC, Hao L, Liberator P, Jones TR, Harris SL, Perez JL, Eiden JJ, Jansen KU, Anderson AS.

Hum Vaccin Immunother. 2017 Feb;13(2):255-265. doi: 10.1080/21645515.2017.1264750. Epub 2016 Dec 14. Review.

3.

Meningococcal vaccine development--from glycoconjugates against MenACWY to proteins against MenB--potential for broad protection against meningococcal disease.

Dull PM, McIntosh ED.

Vaccine. 2012 May 30;30 Suppl 2:B18-25. doi: 10.1016/j.vaccine.2012.01.062. Review.

PMID:
22607895
4.
5.

The epidemiology of meningococcal disease and the impact of vaccines.

Khatami A, Pollard AJ.

Expert Rev Vaccines. 2010 Mar;9(3):285-98. doi: 10.1586/erv.10.3. Review. Erratum in: Expert Rev Vaccines. 2011 Mar;10(3):398.

PMID:
20218857
6.

A combined approach to assess the potential coverage of a multicomponent protein-based vaccine.

Boccadifuoco G, Brunelli B, Pizza MG, Giuliani MM.

J Prev Med Hyg. 2012 Jun;53(2):56-60. Review.

PMID:
23240161
7.

Serogroup B meningococcal vaccines.

Zimmer SM, Stephens DS.

Curr Opin Investig Drugs. 2006 Aug;7(8):733-9. Review.

PMID:
16955685
8.

Meningococcal conjugate vaccines.

Zimmer SM, Stephens DS.

Expert Opin Pharmacother. 2004 Apr;5(4):855-63. Review.

PMID:
15102568
9.

Fast tracking the vaccine licensure process to control an epidemic of serogroup B meningococcal disease in New Zealand.

Lennon D, Jackson C, Wong S, Horsfall M, Stewart J, Reid S.

Clin Infect Dis. 2009 Aug 15;49(4):597-605. doi: 10.1086/603552. Review.

PMID:
19622040
10.

Towards an improved serogroup B Neisseria meningitidis vaccine.

Perrett KP, Pollard AJ.

Expert Opin Biol Ther. 2005 Dec;5(12):1611-25. Review.

PMID:
16318425
11.

Prospects and challenges with introduction of a mono-valent meningococcal conjugate vaccine in Africa.

Okoko BJ, Idoko OT, Adegbola RA.

Vaccine. 2009 Mar 23;27(14):2023-9. doi: 10.1016/j.vaccine.2008.11.092. Epub 2008 Dec 16. Review.

PMID:
19095025
12.

Recent developments in Neisseria meningitidis group A conjugate vaccines.

Frasch CE.

Expert Opin Biol Ther. 2005 Feb;5(2):273-80. Review.

PMID:
15757388
13.

Development of new vaccines against meningococcal disease.

Bröker M.

Arzneimittelforschung. 2003;53(12):805-13. Review.

PMID:
14732960
14.

[Critical review of control strategies for meningococcal meningitis epidemics in Sub-Saharan Africa].

Chippaux JP, Debois H, Saliou P.

Bull Soc Pathol Exot. 2002 Mar;95(1):37-44. Review. French.

PMID:
12012963
15.

Challenges and progress in the development of a serogroup B meningococcal vaccine.

Lewis S, Sadarangani M, Hoe JC, Pollard AJ.

Expert Rev Vaccines. 2009 Jun;8(6):729-45. doi: 10.1586/erv.09.30. Review.

PMID:
19485754
16.

Meningococcal vaccines.

Danzig L.

Pediatr Infect Dis J. 2004 Dec;23(12 Suppl):S285-92. Review.

PMID:
15597071
17.

The use of vaccine antigen characterization, for example by MATS, to guide the introduction of meningococcus B vaccines.

Vogel U, Stefanelli P, Vazquez J, Taha MK, Claus H, Donnelly J.

Vaccine. 2012 May 30;30 Suppl 2:B73-7. doi: 10.1016/j.vaccine.2011.12.061. Review.

PMID:
22607902
18.

Regulatory Pathways That Facilitated Timely Registration of a New Group A Meningococcal Conjugate Vaccine for Africa's Meningitis Belt Countries.

Dellepiane N, Akanmori BD, Gairola S, Jadhav SS, Parker C, Rodriguez C, Srivastava S.

Clin Infect Dis. 2015 Nov 15;61 Suppl 5:S428-33. doi: 10.1093/cid/civ491. Review.

19.

[Meningococcal disease caused by Neisseria meningitidis: epidemiological, clinical, and preventive perspectives].

Almeida-González L, Franco-Paredes C, Pérez LF, Santos-Preciado JI.

Salud Publica Mex. 2004 Sep-Oct;46(5):438-50. Review. Spanish.

PMID:
15521528
20.

Meningococcal vaccines.

Price AA.

Curr Pharm Des. 2007;13(19):2009-14. Review.

PMID:
17627534

Supplemental Content

Support Center